Metabolic syndrome and esophageal and gastric cancer

被引:48
|
作者
Lin, Yulan [1 ,2 ]
Ness-Jensen, Eivind [1 ,3 ]
Hveem, Kristian [3 ]
Lagergren, Jesper [1 ,4 ]
Lu, Yunxia [1 ,5 ]
机构
[1] Karolinska Inst, Dept Mol Med & Surg, Upper Gastrointestinal Surg, S-17176 Stockholm, Sweden
[2] Norwegian Univ Sci & Technol, European Palliat Care Res Ctr, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway
[3] Norwegian Univ Sci & Technol, HUNT Res Ctr, Dept Publ Hlth & Gen Practice, Levanger, Norway
[4] Kings Coll London, Div Canc Studies, London WC2R 2LS, England
[5] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England
基金
瑞典研究理事会;
关键词
Serum lipid; Metabolic syndrome; Hypertension; Neoplasm; Esophagus; Stomach; PROJECT ME-CAN; PROSPECTIVE COHORT; RISK-FACTORS; OBESITY; ADENOCARCINOMA; PREVALENCE; NORWAY; ATHEROSCLEROSIS; CARCINOMA; PRESSURE;
D O I
10.1007/s10552-015-0675-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of the metabolic syndrome in the etiology of esophageal and gastric cancer is unclear. This was a large nationwide cohort study based on data from 11 prospective population-based cohorts in Norway with long-term follow-up, the Cohort of Norway (CONOR) and the third Nord-Trondelag Health Study (HUNT3). The metabolic syndrome was assessed by objective anthropometric and metabolic biochemical measures and was defined by the presence of at least three of the following five factors: increased waist circumference, elevated triglycerides, low high-density lipoprotein cholesterol, hypertension and high glucose. Newly diagnosed cases of esophageal adenocarcinoma, esophageal squamous-cell carcinoma and gastric adenocarcinoma were identified from the Norwegian Cancer Registry. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models with adjustment for potential confounders. Among 192,903 participants followed up for an average of 10.6 years, 62 developed esophageal adenocarcinoma, 64 had esophageal squamous-cell carcinoma and 373 had gastric adenocarcinoma. The metabolic syndrome was significantly associated with an increased risk of gastric adenocarcinoma (HR 1.44, 95 % CI 1.14-1.82), but not associated with esophageal adenocarcinoma (HR 1.32, 95 % CI 0.77-2.26) or esophageal squamous-cell carcinoma (HR 1.08, 95 % CI 0.64-1.83). Increased waist circumference was associated with an increased HR of esophageal adenocarcinoma (HR 2.48, 95 % CI 1.27-4.85). No significant association was found between any single component of the metabolic syndrome and risk of esophageal squamous-cell carcinoma. High waist circumference (HR 1.71, 95 % CI 1.05-2.80), hypertension (HR 2.41, 95 % CI 1.44-4.03) and non-fasting glucose (HR 1.74, 95 % CI 1.18-2.56) were also related to an increased risk of gastric adenocarcinoma in women, but not in men. Metabolic syndrome was associated with an increased risk of gastric adenocarcinoma in women. Of the individual components of the metabolic syndrome, high waist circumference was positively associated with risk of esophageal adenocarcinoma. Positive associations were also observed for women between high waist circumference, hypertension, high non-fasting glucose and risk of gastric adenocarcinoma. However, further evidence is warranted due to the limited number of cases and the inability to effectively identify gastric cardia adenocarcinoma.
引用
收藏
页码:1825 / 1834
页数:10
相关论文
共 50 条
  • [21] Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer
    Janssen, AML
    Bosman, CB
    van Duijn, W
    Oostendorp-van de Ruit, MM
    Kubben, FJGM
    Griffioen, G
    Lamers, CBHW
    van Krieken, JHJM
    van de Velde, CJH
    Verspaget, HW
    CLINICAL CANCER RESEARCH, 2000, 6 (08) : 3183 - 3192
  • [22] Endoscopic resection of gastric and esophageal cancer
    Balmadrid, Bryan
    Hwang, Joo Ha
    GASTROENTEROLOGY REPORT, 2015, 3 (04): : 330 - 338
  • [23] Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma
    Elliott, Jessie A.
    Reynolds, John V.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Surgical strategies for esophageal and gastric cancer
    Schneider, P. M.
    Mueller, M. K.
    Schiesser, M.
    GASTROENTEROLOGE, 2009, 4 (03): : 209 - 223
  • [25] Staging of esophageal and gastric cancer in 2014
    Yegin, E. G.
    Duman, D. G.
    MINERVA MEDICA, 2014, 105 (05) : 391 - 411
  • [26] Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer
    Kim, Eun Hye
    Lee, Hyuk
    Chung, Hyunsoo
    Park, Jun Chul
    Shin, Sung Kwan
    Lee, Sang Kil
    Hyung, Woo Jin
    Lee, Yong Chan
    Noh, Sung Hoon
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2014, 38 (03) : 372 - 378
  • [27] EARLY DIAGNOSIS OF GASTRIC AND ESOPHAGEAL CANCER
    MACADAM, DB
    PRACTITIONER, 1983, 227 (1378) : 537 - 540
  • [28] Novel targets in gastric and esophageal cancer
    Valverde, Claudia Maria
    Macarulla, Teresa
    Casado, Esther
    Javier Ramos, Francisco
    Martinelli, Erika
    Tabernero, Josep
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 59 (02) : 128 - 138
  • [29] Metabolic Syndrome and Clinical Outcomes of Patients with Gastric Cancer: A Meta-Analysis
    Huang, Zhiyang
    Zhou, Jianwei
    Chen, Long
    Zhang, Yibing
    HORMONE AND METABOLIC RESEARCH, 2023, 55 (05) : 333 - 342
  • [30] The Role of Immunotherapy in Esophageal and Gastric Cancer
    Dedecker, Hans
    Teuwen, Laure-Anne
    Vandamme, Timon
    Domen, Andreas
    Prenen, Hans
    CLINICAL COLORECTAL CANCER, 2023, 22 (02) : 175 - 182